Switching planner
Runs in your browser. What you enter stays on your device.
How this works
Most GLP-1 labels say nothing about switching from another GLP-1 medicine, and none gives a dose conversion between different drugs. A few labels do give instructions for moving between forms of the same drug. This planner shows exactly that and nothing more.
- If the label of the medicine you are moving to has an instruction for your switch, you see it with the label's wording.
- If it does not, you see the only starting dose that label states, and a note that the label is silent on switching.
- When a label says two products shouldn't be used together, or aren't interchangeable milligram for milligram, you see that too.
- The cost difference compares the cheapest verified way to pay for your current dose with the cheapest way to pay for the new medicine's starting dose.
It never converts a dose of one drug into a dose of another. Your prescriber makes that decision.
Label starting doses
| Medicine | Form | Starting dose | Minimum time before increasing |
|---|---|---|---|
| Foundayo | Tablet (once daily) | 0.8 mg daily | 30 days |
| Mounjaro | KwikPen (multi-dose, 4 weekly doses) | 2.5 mg weekly | 28 days |
| Mounjaro | Multi-dose vial (4 weekly doses) | 2.5 mg weekly | 28 days |
| Mounjaro | Single-dose pen | 2.5 mg weekly | 28 days |
| Mounjaro | Single-dose vial | 2.5 mg weekly | 28 days |
| Ozempic | Multi-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg) | 0.25 mg weekly | 28 days |
| Ozempic | Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg) | 1.5 mg daily | 30 days |
| Rybelsus | Tablet (once daily) | 3 mg daily | 30 days |
| Saxenda | Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens) | 0.6 mg daily | 7 days |
| Trulicity | Single-dose pen | 0.75 mg weekly | 28 days |
| Wegovy | Single-dose pen (7.2 mg pen is branded WEGOVY HD) | 0.25 mg weekly | 28 days |
| Wegovy | Tablet (once daily) | 1.5 mg daily | 30 days |
| Zepbound | KwikPen (multi-dose, 4 weekly doses) | 2.5 mg weekly | 28 days |
| Zepbound | Multi-dose vial (4 weekly doses) | 2.5 mg weekly | 28 days |
| Zepbound | Single-dose pen | 2.5 mg weekly | 28 days |
| Zepbound | Single-dose vial | 2.5 mg weekly | 28 days |
Every switching statement on the labels
| From | To | What the label says |
|---|---|---|
| Foundayo | Any other product | The Foundayo label says using Foundayo together with another GLP-1 receptor agonist is not recommended. |
| Foundayo Tablet (once daily) | Foundayo Tablet (once daily) | If 7 or more consecutive daily doses of Foundayo are missed, the label says to reinitiate dosage escalation at a lower dosage. It does not say which lower dosage. |
| Mounjaro | Mounjaro | The Mounjaro label gives no dose conversion for changing between presentations (vial, pre-filled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use. |
| Ozempic Multi-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg) | Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg) | The label says patients on the 0.5 mg dose of Ozempic injection may switch to Ozempic tablets, starting 4 mg or 9 mg once daily one week after stopping the injection. It gives no instruction for other Ozempic injection doses. |
| Ozempic Multi-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg) | Rybelsus Tablet (once daily) | The label says patients on the 0.5 mg dose of Ozempic injection may switch to Rybelsus, starting 7 mg or 14 mg once daily one week after stopping the injection. It gives no instruction for other Ozempic injection doses. |
| Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg) | Rybelsus Tablet (once daily) | The label says not to switch during the first 30 days (initiation phase). After that, Ozempic tablets 4 mg corresponds to Rybelsus 7 mg and Ozempic tablets 9 mg to Rybelsus 14 mg, and the new tablet is started the day after stopping the old one. |
| Rybelsus Tablet (once daily) | Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg) | The shared Rybelsus and Ozempic tablets label says the two tablet products are not substitutable on a mg-to-mg basis, so a Rybelsus strength cannot be replaced with the same number of milligrams of Ozempic tablets, or the reverse. |
| Rybelsus Tablet (once daily) | Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg) | The label says not to switch during the first 30 days (initiation phase). After that, Rybelsus 7 mg corresponds to Ozempic tablets 4 mg and Rybelsus 14 mg to Ozempic tablets 9 mg, and the new tablet is started the day after stopping the old one. |
| Saxenda | Any other product | The Saxenda label says using Saxenda together with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. |
| Saxenda Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens) | Saxenda Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens) | If more than 3 days have passed since the last Saxenda dose, the label says to restart at 0.6 mg daily and follow the dosage escalation schedule again. |
| Wegovy | Any other product | The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. |
| Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | The Wegovy label gives no dose conversion for changing between injection presentations (single-dose pen or syringe, FlexTouch pen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use. |
| Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | If 2 or more consecutive weekly doses of Wegovy injection are missed, the label says to reinitiate dosage escalation at a lower dosage. It does not say which lower dosage. The label gives no restart rule for Wegovy tablets. |
| Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | Wegovy Tablet (once daily) | The Wegovy label says adults on the 2.4 mg weekly injection (for cardiovascular risk reduction or weight reduction) may switch to the 25 mg tablet, starting the 25 mg tablet once daily one week after stopping the 2.4 mg injection. |
| Wegovy Tablet (once daily) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | In the tablet dosing section, the Wegovy label says that if the 25 mg once-daily tablet maintenance dosage is not tolerated, a switch to the 1.7 mg once-weekly injection can be considered. |
| Wegovy Tablet (once daily) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | The Wegovy label says patients on the 25 mg tablet may switch to the injection, starting 2.4 mg once weekly the day after stopping the tablets. For patients who do not tolerate the 25 mg tablet, it says to consider the 1.7 mg injection. |
| Wegovy Tablet (once daily) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | For patients with type 2 diabetes on the 25 mg Wegovy tablet who need additional weight reduction, the label says to consider switching to the 1.7 mg injection and then following the injection's dosage escalation. |
| Wegovy Tablet (once daily) | Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD) | The Wegovy label notes that some patients with type 2 diabetes may get subtherapeutic semaglutide blood concentrations on the tablets, and says to consider alternatives, including switching to the injection, if response to the tablets is inadequate. |
| Zepbound | Any other product | The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. |
| Zepbound | Zepbound | The Zepbound label gives no dose conversion for changing between presentations (vial, prefilled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use. |
Frequently asked questions
Is there a dose conversion from Ozempic to Mounjaro?
The Mounjaro label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).
How do I switch from the Wegovy injection to the Wegovy pill?
The Wegovy label says adults on the 2.4 mg weekly injection (for cardiovascular risk reduction or weight reduction) may switch to the 25 mg tablet, starting the 25 mg tablet once daily one week after stopping the 2.4 mg injection. Label text: "Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets. One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily."
How do I switch from the Wegovy pill back to the injection?
The Wegovy label says patients on the 25 mg tablet may switch to the injection, starting 2.4 mg once weekly the day after stopping the tablets. For patients who do not tolerate the 25 mg tablet, it says to consider the 1.7 mg injection. Label text: "Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection. The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection."
Are Rybelsus and Ozempic tablets the same strength?
The shared Rybelsus and Ozempic tablets label says the two tablet products are not substitutable on a mg-to-mg basis, so a Rybelsus strength cannot be replaced with the same number of milligrams of Ozempic tablets, or the reverse. Label text: "RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis."
What does the Zepbound label say about switching from another GLP-1?
The Zepbound label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).
Can I take two GLP-1 medicines during the switch?
The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Label text: "ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended."
Do I need to do anything when changing from a Zepbound pen to a vial or KwikPen?
The Zepbound label gives no dose conversion for changing between presentations (vial, prefilled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use. Label text: "Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation."
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
